Immuron to launch PROIBS® in the United States
MWN-AI** Summary
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, has made significant strides by signing an exclusive distribution agreement with Calmino group AB to launch its product PROIBS® in the United States. This partnership builds on the successful launch of PROIBS® in Australia during FY26. The U.S. market for digestive health supplements is currently valued at $4.16 billion, presenting a substantial opportunity for Immuron to carve out a niche within this landscape.
PROIBS® is designed to alleviate abdominal pain, bloating, and irregular bowel movements, containing AVH200®, which is derived from Aloe barbadensis Mill and is known for its ability to support the intestinal mucosal barrier. The product boasts a strong safety profile, being suitable for long-term use without known interactions with other medications.
A recent usability study involving 1,003 users revealed that 94% found PROIBS® beneficial, with 91% reporting improvements in their daily lives and an impressive 98% willing to recommend it to others. Flavio Palumbo, Chief Commercial Officer of Immuron, emphasized the company’s commitment to a strategic growth plan, leveraging the success of its previous product, Travelan®. He highlighted PROIBS® as a scientifically supported, European certified medical device with over a decade of market presence in Sweden, underscoring its credibility and physician endorsement.
The collaboration with Calmino, which has been effective in Europe for years, is expected to facilitate a seamless introduction into the U.S. market. Tobias Kisker, CEO and founder of Calmino, expressed enthusiasm for further expanding their partnership with Immuron, indicating a promising future in developing this innovative digestive health solution across multiple continents.
MWN-AI** Analysis
**Market Advice Analysis for Immuron's Launch of PROIBS® in the U.S.**
With Immuron Limited’s recent agreement to distribute PROIBS®, a medical device targeting abdominal discomfort, in the U.S. in collaboration with Calmino group AB, there are notable investment implications to consider. The U.S. digestive/gut health supplement market stands at approximately $4.16 billion, indicating significant demand and potential for market entry.
PROIBS® is backed by a decade of positive outcomes in Swedish pharmacies, further supported by a usability study of 1,003 users showing a remarkable 94% efficacy rate. Such solid user endorsement will be crucial in penetrating the competitive U.S. market. The product's safety profile—characterized by long-term usability and no known medication interactions—positions it well against competitors, enhancing its attractiveness to both consumers and healthcare providers.
As Immuron looks to expand its presence, focusing on strategic marketing will be essential. Leveraging the existing relationship with healthcare professionals can further bolster credibility and adoption rates. Additionally, targeting online platforms for direct consumer engagement will capitalize on trends towards transparent health solutions, particularly among health-conscious millennials and Gen Z.
From a financial perspective, investors should monitor the support from physicians and dietitians as it could directly correlate with early sales performance and brand trust. The presence of other Immuron products like Travelan® in the U.S. offers a pre-established channel for cross-promotion, potentially accelerating PROIBS®’ market penetration.
However, it's prudent to remain cautious regarding regulatory hurdles and competition. As Immuron navigates this debut, staying agile and responsive to market feedback will refine its growth strategy. Given the positive momentum from international operations, investing in Immuron may present a bullish opportunity as PROIBS® paves the way in the flourishing U.S. digestive health sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MELBOURNE, Australia, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to announce that it has executed an exclusive distribution agreement for PROIBS® in the United States with Calmino group AB. Immuron launched PROIBS® in Australia during FY26.
The overall U.S. digestive/gut health supplement market is valued at $4.16 billion (Mordor Intelligence). Immuron is targeting a subset of this market with PROIBS®. PROIBS® is a medical device used for abdominal pain, bloating and unsettled bowel movements (diarrhoea and/or constipation). PROIBS® contains AVH200®, derived from the plant, Aloe barbadensis Mill. AVH200® has gel forming components which support the intestinal mucosal barrier. PROIBS® is suitable for long-term use, with an excellent safety profile and no interactions with other medications known. Science-driven innovative Calmino group AB, the developer of PROIBS®, conducted a usability study among 1,003 users. PROIBS® was helpful for 94% of them. 91% of the users experienced an improvement in daily life and 98% would recommend PROIBS® to someone else.
Flavio Palumbo, Chief Commercial Officer said “Following the rapid growth of Travelan® sales in the US, we have developed a commercial growth strategy to bring a portfolio of innovative digestive health products to market. PROIBS® is a great opportunity to further expand our digestive health portfolio by providing our customers with a proven premium product that delivers improvement in daily life. With PROIBS®, we are able to provide an innovative and European certified medical device. The product has been on the Swedish pharmacy market for more than a decade. Because it is backed by science and recommended by physicians and dietitians, we can promote PROIBS® with absolute confidence. We are looking forward to offering a solution that truly improves the livability of the affected people.”
Tobias Kisker, CEO and founder of Calmino group AB, commented “We are immensely proud to further expand our collaboration with Immuron. What started with PROIBS® in Australia is now developing into a partnership across two continents, with the United States becoming our next important market together. We look forward to building on the strong relationship we have established with Immuron.”
This release has been authorised by the directors of Immuron Limited.
COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
steve@immuron.com
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
For more information visit: https://www.immuron.com.au/ and https://www.travelan.com
Subscribe to Immuron’s InvestorHub: Here
About Calmino group AB
Calmino group AB is a Swedish life science company founded in 2003 and based at Sahlgrenska Science Park in Gothenburg, Sweden. The company develops and commercializes science-driven products within digestive health. Its lead product, PROIBS®, has been available in European markets for more than a decade and is currently distributed internationally.
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.
FAQ**
How does Immuron Limited (IMC) plan to differentiate PROIBS® from competitors in the U.S. digestive health market valued at $4.billion?
What strategies will IMC implement to leverage the 94% positive feedback from PROIBS® usability studies in future marketing campaigns?
Can IMC provide insights into the expected growth trajectory for PROIBS® now that it has entered the U.S. market through Calmino group AB?
What measures is IMC taking to ensure the successful integration of PROIBS® into their existing portfolio alongside Travelan®?
**MWN-AI FAQ is based on asking OpenAI questions about Immuron Limited (NASDAQ: IMRN).
NASDAQ: IMRN
IMRN Trading
-0.9% G/L:
$1.10 Last:
690 Volume:
$1.10 Open:
IMRN Latest News
